Viking Therapeutics, Inc. - Common Stock (NQ:VKTX)

26.46 -0.40 (-1.49%)

Delayed Quote Updated: 9:47 AM EDT, Oct 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Viking Therapeutics, Inc. - Common Stock

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026

Via Investor Brand Network

InvestorNewsBreaks – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) Featured in BioMedWire Editorial on Next-Generation GLP-1 Innovation

May 13, 2026

Via Investor Brand Network

The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial

April 23, 2026

From stem cell therapies for frailty to α-Klotho protein programs and GLP-1 drug classes now labeled "longevity therapeutics," the science and the capital have finally met

From Equity Insider

Via GlobeNewswire

Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)

August 22, 2025

Via AB Newswire

Viking Therapeutics Inc. (NASDAQ: VKTX) is a Stock Spotlight on 5/23

May 23, 2023

Via Investor Brand Network

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

May 13, 2026

From BioMedWire

Via GlobeNewswire

Profusa Inc (NASDAQ: PFSA) Establishes a distributor partner in Spain for Lumee Oxygen platform

August 18, 2025

Via AB Newswire

Is Viking Therapeutics Ready For Another Surge?

September 27, 2024

Viking Therapeutics' promising weight loss drug could revolutionize the obesity market and propel the company's stock price to new highs.

Via MarketBeat

Viking Therapeutics Is Having a Year to Remember: Time to Buy?

September 19, 2024

Viking Therapeutics Inc. (NASDAQ: VKTX) has surged 238% year-to-date and 326% over the past year, far outpacing its sector and market.

Via MarketBeat

Viking Therapeutics: Pharma Stock Soars on Positive Earnings

July 25, 2024

Viking Therapeutics stock soars on clinical trial results and a solid earnings beat, signaling a potential market shake-up in the biopharmaceutical sector.

Via MarketBeat

Topics Earnings

Eli Lilly Stock Leads in GLP-1 Race with its Triple Agonist Drug

July 09, 2024

Global pharmaceutical company Eli Lilly & Co. (NYSE: LLY) has been in a GLP-1 arms race with its FDA-approved therapies Mounjaro and Zepbound. It's been

Via MarketBeat

Altimmune Stock: Is Its GLP-1 Drug the Next Ozempic Killer?

July 03, 2024

Clinical-state biopharmaceutical company Altimmune Inc. (NASDAQ: ALT) focuses on developing peptide-based therapeutics for obesity and chronic liver diseases

Via MarketBeat

Pfizer Stock is Ready to Stage a Turnaround on GLP-1 Hopes

July 02, 2024

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) has been trying to enter the weight-loss treatment trend dominated by GLP-1 drug makers like Ozempic and Wegovy

Via MarketBeat

Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market

July 01, 2024

Global pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.

Via MarketBeat

Eli Lilly Gains on the GLP-1 Weight Loss Phenomenon

May 06, 2024

Eli Lilly stock continues to move higher after the company reported continuing momentum for its flagship GLP-1 weight loss drugs

Via MarketBeat

Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?

April 22, 2024

The GLP-1 weight loss trend continues to flourish, and the ante keeps rising; see how the winner between Wegovy and Zepbound can help your portfolio

Via MarketBeat

Can Altimmune get its GLP-1 Drug to Market Before Cash Rush Out?

April 09, 2024

Altimmune has a GLP-1 candidate in Phase 2 trials, but the company continues to burn cash and may need a big pharma partner to get its drug to market

Via MarketBeat

MarketBeat Week in Review – 4/1 - 4/5

April 06, 2024

Equities lost ground this week as investors consider the effect of fewer rate cuts, rising oil prices, and robust job gains ahead of a new earnings season

Via MarketBeat

Topics Economy

Viking Therapeutics Surges Sentiment for Triple Threat GLP-1Pill

April 03, 2024

Viking Therapeutics is preparing to be the next entry into the GLP-1 Market, and VKTX stock is soaring as analysts start to bid the stock higher

Via MarketBeat

7 Stocks That Will Drive the Weight Loss Drugs Market

March 28, 2024

The booming weight loss drug market presents both lucrative potential and significant risks for investors seeking to capitalize on the global obesity crisis.

Via MarketBeat

Vivani Medical Surges on its Ozempic-Like Weight-Loss Implant

March 06, 2024

The Ozempic craze continues to make headlines in the medical sector, and GLP-1 drug stocks such as Vivani Medical continue to surge higher

Via MarketBeat

Viking Therapeutics Inc. (NASDAQ: VKTX) Near Top of Volume Charts in Tuesday Trading

February 27, 2024

Via Investor Brand Network

2 biotechs with promising weight-loss drugs coming

January 16, 2024

Clinical weight-loss medications have been making headlines as GLP-1 drugs like Novo Nordisk A/S (NYSE: NVO) owned Ozempic and Wegovy and Eli Lilly and Co.

Via MarketBeat

Melanocortin Receptor R&D to Target Increasing Prevalence of Obesity-Related Disorders

October 19, 2023

EQNX::TICKER_START (NYSE:PTN),(NASDAQ:RYTM),(NASDAQ:VKTX),(NASDAQ:GPCR),(NYSE:NVO) EQNX::TICKER_END

Via FinancialNewsMedia

Lilly Shares Up On Versanis Deal Amid Weight-Loss Drug Gold Rush

July 24, 2023

A bid to acquire Versanis boosts Eli Lilly & Co. by 2.80% in the past week, as the competition to develop the most effective weight-loss drug intensifies.

Via MarketBeat

Here are 2 Top Drug Makers Leading the Way in Weight Loss Drugs

April 17, 2023

The topic of weight loss drugs has been making recent headlines. The positive phase 1 clinical trial for Viking Therapeutics Inc. (NASDAQ: VKTX) GLP-1 treatme

Via MarketBeat

Viking Therapeutics Inc. (NASDAQ: VKTX) Records 52-Week High Tuesday Morning

March 28, 2023

Via Investor Brand Network

Here’s Why Viking Therapeutics Rose Over 50% on Obesity Drug Data

March 28, 2023

Clinical-stage biotechnology company Viking Therapeutics, Inc. (NASDAQ: VKTX) stock jumped more than 50% on positive Phase 1 data on its novel dual GLP-1/GLP

Via MarketBeat

Why Did Viking Therapeutics Stock Skyrocket

December 21, 2022

VKTX stock is young but strong and they have excellent potential, particularly following successful trial results from Madrigal Pharma's recent drug trial.

Via MarketBeat

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.